Sarilumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sarilumab
- Sarilumab: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
Using no additional skill — this is a direct content-generation task with a fully specified template; I’ll follow the Evidence Pack extraction rules exactly.
Sarilumab: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
One-Sentence Summary
Sarilumab is a human monoclonal antibody blocking the IL-6 receptor alpha (IL-6Rα), originally developed for rheumatoid arthritis (per literature on file; the drug currently holds no formal marketing authorization in this dataset). The TxGNN model’s top-ranked prediction is Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome, but this candidate currently has 0 clinical trials and 0 publications supporting it, and has been flagged by evidence review as a likely knowledge-graph noise signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis (identified from literature evidence in this pack; no formal EU/Taiwan marketing authorization on file) |
| Predicted New Indication | Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome |
| TxGNN Prediction Score | 98.50% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not directly recorded in the drug-level fields of this evidence pack. However, literature captured elsewhere in the pack (PMID 32451909) confirms that sarilumab is a human monoclonal antibody blocking the interleukin-6 receptor alpha (IL-6Rα), approved for moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to conventional DMARDs.
Colobomatous microphthalmia-rhizomelic dysplasia syndrome is a rare congenital disorder involving ocular coloboma/microphthalmia and skeletal (rhizomelic) dysplasia, driven by developmental gene abnormalities rather than cytokine-mediated inflammation. There is no known biological pathway connecting IL-6/IL-6R signaling to this developmental syndrome.
The evidence review explicitly concludes this is a knowledge-graph noise prediction: the TxGNN embedding score is high, but there is no mechanistic plausibility, no clinical trial activity, and no literature support. This prediction should not be interpreted as a genuine repurposing signal for sarilumab.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Sarilumab currently holds no recorded marketing authorization in this dataset (market status: Not marketed; 0 authorizations on file).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (colobomatous microphthalmia-rhizomelic dysplasia syndrome) has no supporting clinical trials, no supporting literature, and no plausible mechanistic link to IL-6Rα blockade — it is assessed as a model noise artifact rather than a genuine repurposing signal.
To proceed, the following is needed:
- Mechanism of action (MOA) data for sarilumab (currently a data gap, DG002)
- TFDA/EU label warnings and contraindications (currently a data gap, DG001; blocking for any safety pre-assessment)
- If repurposing exploration for sarilumab continues, evaluation should instead focus on the pack’s mechanistically stronger candidates with existing L4 evidence — inflammatory bowel disease and plasma cell myeloma — both currently at decision stage S1 (“Research Question”) rather than this noise-flagged L5 prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.